Skip to Main Content

Paper Details

Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.
Supportive Care in Cancer
18
2016
Bevacizumab, CHF, DLVEF, HTN, MI, Patients, Sorafenib, arrhythmia, bevacizumab, cancer, cardiovascular, cardiovascular toxicities, congestive heart failure, hypertension, myocardial infarction, patients, sorafenib, sunitinib, trastuzumab
Author NameAffiliation
Linda S EltingDepartment of Health Services Research, University of Texas MD Anderson Cancer Center
  • 1 - 1

Datasets

Release 1.2